您要查找的是不是：
- The study aimed to show a 35% increase in progression free survival when the MabThera-based combination was used. 研究表明使用基于美罗华的联合治疗，可以将无进展生存提高35%25。
- Keywords Ovarian neoplasms;Overall survival;Progression free survival;Prognostic factor;Endothelial growth factors;Thymidine phosphorylase;Microvessel density; 卵巢肿瘤;总生存期;无进展生存期;预测因子;内皮生长因子;胸苷磷酸化酶;微血管密度;
- Progression free survival 无瘤生存期
- Patients with poor prognosis had a shorter progression period and shorter disease free survival period. They needed more chemotherapy treatment, and maintenance treatment. 未得到良好治疗的病人疾病发展更迅速,生存机会更小。他们需要更多的化学治疗和维持治疗。
- The preliminary result suggested that AHSCT could prolong the disease - free survival for AL, HD and ALC. 初步结果提示AHSCT能延长AL、HD和ALC患者的无病存活期。
- The 3-year overall survival (OS) and disease free survival ( DFS) was 66. 3% and 59. 5% , respectively. 3年总生存率和无病生存率分别为66.;3%25和59
- The NO16966 study also demonstrated significantly superior progression free surial（PFS）in patients treated with XELOX and B（XELOX+B） than patients ... 我正在翻译一篇关于肿瘤药物临床试验的文章，遇到几个不好翻译的词，恳请高手相助，不甚感激！
- The 5 -year overall survival (OS) and disease free survival (DFS) were 89% and 73%,respectively. 全组5年总生存率和无病生存率分别为89%25和73%25。
- The five-year survival rate (SR),disease free survival rate (DFSR) were 65 6% and 54 5%,respectively. 总的5年生存率、无瘤生存率分别为65.;6%25和54
- Tumor size, pTNM, vascular invasion and MILAN-criteria were risk factors of tumor recurrence, and so that affecting the tumor free survival. 肿瘤的大小、TNM分期、有无脉管浸润、是否符合Milan标准均能反映肿瘤复发的风险,而肿瘤的TNM分期及肿瘤有无脉管浸润能进一步影响患者术后的无瘤存活率。
- Technical progress frees humankind of heavy labour and inconvenience. 技术进步将人类从繁重的体力劳动和生活不便中解放出来。
- Univariate analysis showed that patients with low expression of VEGF and MVD had longer disease free survival (DFS) and overall suvival(OS). 单因素预后分析显示，VEGF及MVD低表达者无病生存期(DFS)及总生存期(OS)长于高表达者。
- The overall 5 ,10 year accumulated survival rates (ASR) were 85.1% and 73.2%. The 5 ,10 year disease free survival rates (DFSR) were 68.0% and 63.6% , respectively. 全组 5、10年总生存率分别为 85 .;1%25和 73
- Five-and 10-year rates of recurrence free survival from the first dayof therapy ere 51.75% and 31.23%. The median recurrence free survival time was 6 years. Kaplan-Meier 法计算5年、10年无瘤生存率分别为51.;75%25和31
- Postoperative adjuvant FCF chemotherapy improves 3-year disease- free survival rate and the 5-year survival rate of the patients with Dukes B stage colorectal carcinoma. Dukes B期大肠癌根治术后给予FCF方案辅助化疗能够提高患者3年无瘤生存率和5年生存率;
- CDC91L1 expression level correlated to the recurrence free survival（RFS）of patients with superficial bladder urothelial cell carcinoma (Log rank, P＜0.05）. 4．CDC91L1蛋白表达水平与浅表性膀胱癌术后无复发生存时间相关（Log秩和检验，P＜0.;05）。
- Results In the 74 patients in treatment group, 4 relapsed, 8 metastasized, and 1 patient died;the median disease free survival time (mDFS) for these 13 cases were 6.1 years. 结果中药组74例中，复发4例，转移8例，死亡1例，此13例患者的中位无病生存期6.;1年；
- The overall 5 year survival rate (OS), disease free survival rate (DFS), distant metastasis free rate(DMF)and local regional free rate (LRF) were 57.1%, 52.9%, 61.0% and 83.3%, respectively. 5年总生存率 (OS)为 5 7.;1%25;5年无瘤生存率 (DFS)为 5 2
- Methods HD-AraC based protocols were used as early and regular intensification regimens to treat childhood AML,and the long-term disease free survival(DFS) rate was calculate with Kaplan-Merier method. 方法以HD-AraC为主的联合方案作为儿童AML长期化疗中的早期和定期强化治疗,采用Kaplan-Merier法统计长期无病生存(DFS)率。
- Moreover, patients with higher blood vessels positive area or higher MVD had lower disease free survival rate (DFSR) or overall survival rate (OSR) than those with lower blood vessels positive area or lower MVD. 高血管阳性反应总面积组及高MVD组总生存率(OSR)和无瘤生存率(DFSR)低于低血管阳性反应总面积组和低MVD组(P<0.;005)。
